Eli Lilly Shares Purchased by Southeast Asset Advisors

Investment firm increases stake in pharmaceutical giant by over 500%

Published on Feb. 16, 2026

Got story updates? Submit your updates here. ›

Southeast Asset Advisors LLC significantly increased its position in Eli Lilly and Company (NYSE:LLY) during the 3rd quarter, boosting its holdings by 562.4% to 4,286 shares worth $3.27 million. This comes as Eli Lilly, a global pharmaceutical company headquartered in Indianapolis, Indiana, has seen its stock price rise over the past year amid strong financial performance.

Why it matters

The substantial increase in Southeast Asset Advisors' Eli Lilly holdings suggests the investment firm sees significant upside potential in the stock. As a major pharmaceutical company, Eli Lilly's financial results and stock price movements are closely watched by investors and analysts as indicators of the broader industry's health.

The details

According to a regulatory filing, Southeast Asset Advisors added 3,639 Eli Lilly shares to its portfolio during the 3rd quarter, bringing its total position to 4,286 shares. This represents a 562.4% increase compared to the prior quarter. Eli Lilly's stock has risen steadily over the past year, closing at a 52-week high of $1,133.95 on Monday.

  • Southeast Asset Advisors increased its Eli Lilly holdings during the 3rd quarter of 2026.
  • Eli Lilly's stock price reached a 52-week high of $1,133.95 on Monday, February 16, 2026.

The players

Southeast Asset Advisors LLC

An investment management firm that significantly increased its stake in Eli Lilly and Company during the 3rd quarter of 2026.

Eli Lilly and Company

A global pharmaceutical company headquartered in Indianapolis, Indiana that has seen its stock price rise over the past year amid strong financial performance.

Got photos? Submit your photos here. ›

The takeaway

The substantial increase in Southeast Asset Advisors' Eli Lilly holdings suggests the investment firm sees significant upside potential in the pharmaceutical company's stock, which has been on a steady rise over the past year. This reflects broader investor confidence in Eli Lilly's financial performance and growth prospects within the pharmaceutical industry.